Download by
Scanning QR Code
No Data
US Stock MarketDetailed Quotes
GOVX GeoVax Labs
Watchlist
0.5189
+0.0081+1.59% Trading 09/28 14:18 ET
0.5300High0.5100Low40.90KVolume
0.5300Open0.5108Pre Close21.16KTurnover0.16%Turnover RatioLossP/E (TTM)13.72MMarket Cap1.390052wk HighLossP/E (Static)26.44MShares0.505552wk Low0.80P/B13.52MFloat Cap8.7100Historical High--Dividend TTM26.06MShs Float0.5055Historical Low--Div YieldTTM3.92%Amplitude0.5170Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About GeoVax Labs Company
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
News
GeoVax Labs(GOVX.US) Officer Buys US$5,019.56 in Common Stocks
$GeoVax Labs(GOVX.US)$ Officer McKee Kelly T. Jr. purchased 9,653 shares of Common Stocks on Sep 25, 2023 at an average price of $0.52 for a total value of $5,019.56.Source: Announcement What is state
GeoVax to Participate in Upcoming October Investor and Industry Events
Company to Provide Updates on Phase 2 Clinical Trialsfor Next Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax
GeoVax Labs Secures License Agreement With ProBioGen